July 31, 2025

Reporting of Health-Related Quality of Life Outcome Measures in Genotype based Targeted Therapies for Advanced Cancers

View Full Paper

Ask AI

Bookmark

Authors

Discussion

Analysis of HRQoL reporting in randomised controlled trials of genotype-based therapies for advanced cancers highlights significant gaps.

Most trials of genotype based targeted therapies did not report health-related quality of life as a primary endpoint.
Among 61 trials evaluated, only 35 included HRQoL as a secondary endpoint, and 17 reported it in the primary publication.
There is a noticeable decline in the inclusion and reporting of HRQoL over time, especially post-2020.
Compliance with CONSORT-PRO guidelines is poor, with no trials adequately addressing HRQoL in their study design.

Liu et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark